Skip to main content
. 2018 Nov 5;9:2552. doi: 10.3389/fimmu.2018.02552

Figure 6.

Figure 6

CD16.NK-92 and alefacept significantly reduce HIV DNA in vitro. (A) Percent of whole representation of CD4+ T cell memory subsets by HIV+ donor with no treatment, after 3 day co-culture with CD16.NK-92 and 10 μg/mL alefacept or IgG1 control antibody. (B) Absolute counts of CD27+ CD45RA– T(CM/TM) subset in HIV+ donors after 3 days in co-culture with CD16.NK-92 and 10 μg/mL alefacept or IgG1 control antibody. (C) HIV DNA copies per million CD4+ T cells as measured by quantitative PCR, with no treatment or after 3 day co-culture with CD16.NK-92 and 10 μg/mL alefacept or IgG1 control antibody. Samples in which HIV gag DNA was not detectable are indicated with N.D. Dotted line represents the limit of detection (L.O.D.) of 2 copies of HIV gag DNA copies/106 CD4+ T cells. Mean and SEM shown for 3 qPCR reactions of same sample and 6 HIV+ donors, *P ≤ 0.05, **P ≤ 0.01.